Candriam S.C.A. Moon Lake Immunotherapeutics Transaction History
Candriam S.C.A.
- $16.9 Billion
- Q4 2024
A detailed history of Candriam S.C.A. transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Candriam S.C.A. holds 227,476 shares of MLTX stock, worth $9.13 Million. This represents 0.07% of its overall portfolio holdings.
Number of Shares
227,476
Previous 239,000
4.82%
Holding current value
$9.13 Million
Previous $12.1 Million
0.32%
% of portfolio
0.07%
Previous 0.07%
Shares
3 transactions
Others Institutions Holding MLTX
# of Institutions
137Shares Held
58.1MCall Options Held
124KPut Options Held
96.9K-
Bvf Inc San Francisco, CA19.8MShares$792 Million39.28% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$341 Million35.64% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.34MShares$134 Million0.02% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.77MShares$111 Million2.15% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.19MShares$87.7 Million0.02% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $1.48B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...